A Phase IB/II, Single Arm, Multi-center Study of Nivolumab in Combination With Eribulin in HER2 Negative Metastatic Breast Cancer Patients

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 26 Aug 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Eribulin (Primary) ; Nivolumab (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer; Triple negative breast cancer
Focus Adverse reactions; Therapeutic Use
Acronyms KORNELIA

06 Aug 2024 Results assessing exploratory genomic and transcriptomic analyses of pretreatment tumor tissues from patients enrolled in this trial, published in the Cancer Immunology Immunotherapy.
14 Oct 2023 Results (n=45) assessing efficacy and safety of nivolumab and eribulin combination therapy for metastatic breast cancer (BC) in Asian populations published in the European Journal of Cancer
07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com